From drop to double: Akero’s surging stock

What It Covers

Akero CEO Andrew Cheng discusses the company's development of efroxiferman for MASH treatment, explaining how a failed 36-week trial result transformed into success at 96 weeks, making Akero the leading candidate for treating cirrhotic MASH patients with 50% five-year mortality rates.

Key Questions Answered

• •Clinical trial design strategy: Akero designed their SYMMETRY phase 2 trial with dual endpoints at 36 weeks and 2 years, providing a safety net when initial results failed statistical significance. This extended timeline allowed the drug to demonstrate doubled efficacy versus placebo at 96 weeks, proving cirrhotic patients need longer treatment duration than initially assumed.
• •FGF21 dual mechanism advantage: Efroxiferman works through two pathways - directly inhibiting new collagen fiber deposition (antifibrotic) and removing liver fat (anti-steatotic). This dual action differs from Resdiffra's thyroid hormone receptor approach and addresses both immediate fibrosis prevention and secondary healing through fat reduction, potentially offering superior outcomes in advanced disease.
• •Cirrhotic MASH market opportunity: F4 cirrhotic patients face 50% mortality at five years, yet no therapy has ever succeeded in clinical trials regardless of mechanism, company, or duration. Akero's positive 96-week data represents the first successful result in this population, creating a clear path to becoming first approved therapy for these highest-risk patients.
• •Biotech capital navigation framework: Successfully advancing large MASH trials requires multiple capital raises serving as market validation checkpoints. Akero maintained investor support through bear and bull markets by delivering clinical data that justified continued investment, competing against 800 biotech companies for limited capital while meeting FDA standards identical to large pharmaceutical companies.